Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.

Odawara M, Miyagawa J, Iwamoto N, Takita Y, Imaoka T, Takamura T

Diabetes, obesity & metabolism8 Jan 2016Cited by 49 (Europe PMC)

PMID26661514PMCIDPMC5064615DOI10.1111/dom.12602PepBankPUB-26661514

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, four liraglutide-treated patients (2.9%) reported hypoglycaemia over 52 weeks, with no severe event; the rate was the same as with dulaglutide.
In plain wordsIn Japanese adults with type 2 diabetes, 2.9% of those on liraglutide had low blood sugar, none severe, the same share as with dulaglutide.
Peptide
Liraglutide
Outcome
Not applicableHypoglycaemia
Study
n = 141
Comparator
Dulaglutide 0.75 mg once weekly
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.9 mg once daily · 52 weeksAs given in this study (human).
Measurements
Patients with hypoglycaemia
2.9%
liraglutide 0.9 mg
Source sentences
Summary
Eight dulaglutide-treated (2.9%) and four liraglutide-treated (2.9%) patients reported hypoglycaemia, with no event being severe.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a phase III, randomized, 52-week (26-week primary endpoint), active- and placebo-controlled trial comparing 492 Japanese patients (dulaglutide, n = 281; liraglutide, n = 141; and placebo, n = 70).
Report a problemFND-2666151401
02HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, body weight was generally stable through 52 weeks in both the liraglutide and the dulaglutide group.
In plain wordsIn Japanese adults with type 2 diabetes, body weight stayed generally stable over 52 weeks on liraglutide, and on dulaglutide.
Peptide
Liraglutide
Outcome
No significant changeBody weight through 52 weeks
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg once weekly
Outcome group
Body weight · Metabolic and weight
Studied dose
0.9 mg once daily · 52 weeksAs given in this study (human).
Source sentences
Summary
Body weight was generally stable in both groups through 52 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a phase III, randomized, 52-week (26-week primary endpoint), active- and placebo-controlled trial comparing 492 Japanese patients (dulaglutide, n = 281; liraglutide, n = 141; and placebo, n = 70).
Report a problemFND-2666151402
03HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes treated with dulaglutide or liraglutide, the most frequent adverse events were nasopharyngitis, constipation, nausea and diarrhoea.
In plain wordsIn Japanese adults with type 2 diabetes on dulaglutide or liraglutide, the most common side effects were nasopharyngitis, constipation, nausea and diarrhoea.
Peptide
Liraglutide
Outcome
Not applicableMost frequent adverse events (nasopharyngitis, constipation, nausea, diarrhoea)
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg once weekly
Outcome group
Adverse events · Whole body
Studied dose
0.9 mg once daily · 52 weeksAs given in this study (human).
Source sentences
Summary
The most frequently reported adverse events were nasopharyngitis, constipation, nausea and diarrhoea.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a phase III, randomized, 52-week (26-week primary endpoint), active- and placebo-controlled trial comparing 492 Japanese patients (dulaglutide, n = 281; liraglutide, n = 141; and placebo, n = 70).
Report a problemFND-2666151403
04HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, dulaglutide reduced HbA1c more than liraglutide at week 52.
In plain wordsDulaglutide reduced long-term blood sugar more than liraglutide in Japanese patients with type 2 diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Comparator
Liraglutide 0.9 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Measurements
HbA1c least squares mean difference
−0.2 percentage points
dulaglutide versus liraglutide
95% CI lower
−0.39 percentage points
HbA1c difference
95% CI upper
−0.01 percentage points
HbA1c difference
P value
0.04
between groups
Source sentences
Summary
At week 52, dulaglutide decreased HbA1c significantly from baseline compared with liraglutide [least squares mean difference: -0.20; 95% confidence interval (CI) -0.39, -0.01; p = 0.04].
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the efficacy and safety of once-weekly dulaglutide 0.75 mg monotherapy compared with once-daily liraglutide 0.9 mg in Japanese patients with type 2 diabetes (T2D) for 52 weeks.
Summary · context
The present paper reports results for patients treated with dulaglutide and patients treated with liraglutide for 52 weeks.
Report a problemFND-2666151404
05HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, dulaglutide decreased pre-dinner glucose more than liraglutide at week 52.
In plain wordsDulaglutide decreased blood sugar before dinner more than liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePre-dinner blood glucose
Study
n: not reported in source
Comparator
Liraglutide 0.9 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
At week 52 (last observation carried forward), dulaglutide significantly decreased pre- and post-dinner blood glucose (BG) levels, the mean of seven-point self-monitored BG profiles, the mean of all postprandial BG levels and circadian variation compared with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the efficacy and safety of once-weekly dulaglutide 0.75 mg monotherapy compared with once-daily liraglutide 0.9 mg in Japanese patients with type 2 diabetes (T2D) for 52 weeks.
Summary · context
The present paper reports results for patients treated with dulaglutide and patients treated with liraglutide for 52 weeks.
Report a problemFND-2666151405
06HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, dulaglutide decreased post-dinner glucose more than liraglutide at week 52.
In plain wordsDulaglutide decreased blood sugar after dinner more than liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePost-dinner blood glucose
Study
n: not reported in source
Comparator
Liraglutide 0.9 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
At week 52 (last observation carried forward), dulaglutide significantly decreased pre- and post-dinner blood glucose (BG) levels, the mean of seven-point self-monitored BG profiles, the mean of all postprandial BG levels and circadian variation compared with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the efficacy and safety of once-weekly dulaglutide 0.75 mg monotherapy compared with once-daily liraglutide 0.9 mg in Japanese patients with type 2 diabetes (T2D) for 52 weeks.
Summary · context
The present paper reports results for patients treated with dulaglutide and patients treated with liraglutide for 52 weeks.
Report a problemFND-2666151406
07HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, dulaglutide decreased mean seven-point glucose more than liraglutide at week 52.
In plain wordsDulaglutide decreased average blood sugar across seven daily measurements more than liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseMean seven-point self-monitored blood glucose
Study
n: not reported in source
Comparator
Liraglutide 0.9 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
At week 52 (last observation carried forward), dulaglutide significantly decreased pre- and post-dinner blood glucose (BG) levels, the mean of seven-point self-monitored BG profiles, the mean of all postprandial BG levels and circadian variation compared with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the efficacy and safety of once-weekly dulaglutide 0.75 mg monotherapy compared with once-daily liraglutide 0.9 mg in Japanese patients with type 2 diabetes (T2D) for 52 weeks.
Summary · context
The present paper reports results for patients treated with dulaglutide and patients treated with liraglutide for 52 weeks.
Report a problemFND-2666151407
08HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, dulaglutide decreased mean postprandial glucose more than liraglutide at week 52.
In plain wordsDulaglutide decreased average blood sugar after meals more than liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseMean postprandial blood glucose
Study
n: not reported in source
Comparator
Liraglutide 0.9 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
At week 52 (last observation carried forward), dulaglutide significantly decreased pre- and post-dinner blood glucose (BG) levels, the mean of seven-point self-monitored BG profiles, the mean of all postprandial BG levels and circadian variation compared with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the efficacy and safety of once-weekly dulaglutide 0.75 mg monotherapy compared with once-daily liraglutide 0.9 mg in Japanese patients with type 2 diabetes (T2D) for 52 weeks.
Summary · context
The present paper reports results for patients treated with dulaglutide and patients treated with liraglutide for 52 weeks.
Report a problemFND-2666151408
09HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, dulaglutide decreased circadian glucose variation more than liraglutide at week 52.
In plain wordsDulaglutide decreased daily blood sugar variation more than liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseCircadian blood glucose variation
Study
n: not reported in source
Comparator
Liraglutide 0.9 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
At week 52 (last observation carried forward), dulaglutide significantly decreased pre- and post-dinner blood glucose (BG) levels, the mean of seven-point self-monitored BG profiles, the mean of all postprandial BG levels and circadian variation compared with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the efficacy and safety of once-weekly dulaglutide 0.75 mg monotherapy compared with once-daily liraglutide 0.9 mg in Japanese patients with type 2 diabetes (T2D) for 52 weeks.
Summary · context
The present paper reports results for patients treated with dulaglutide and patients treated with liraglutide for 52 weeks.
Report a problemFND-2666151409
10HumanRandomized controlled trialSafety outcome
In Japanese patients with type 2 diabetes, hypoglycaemia occurred in 2.9% of dulaglutide patients and 2.9% of liraglutide patients.
In plain wordsLow blood sugar occurred in 2.9% of patients receiving either dulaglutide or liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHypoglycaemia
Study
n: not reported in source
Comparator
Liraglutide 0.9 mg once daily
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Measurements
Patients with hypoglycaemia
8 patients
dulaglutide
Hypoglycaemia incidence
2.9%
dulaglutide
Patients with hypoglycaemia
4 patients
liraglutide
Hypoglycaemia incidence
2.9%
liraglutide
Source sentences
Summary
Eight dulaglutide-treated (2.9%) and four liraglutide-treated (2.9%) patients reported hypoglycaemia, with no event being severe.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the efficacy and safety of once-weekly dulaglutide 0.75 mg monotherapy compared with once-daily liraglutide 0.9 mg in Japanese patients with type 2 diabetes (T2D) for 52 weeks.
Summary · context
The present paper reports results for patients treated with dulaglutide and patients treated with liraglutide for 52 weeks.
Report a problemFND-2666151414
11HumanRandomized controlled trialSafety outcome
In Japanese patients with type 2 diabetes receiving dulaglutide, no reported hypoglycaemia event was severe.
In plain wordsNo reported low blood sugar event was severe in patients receiving dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSevere hypoglycaemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
Eight dulaglutide-treated (2.9%) and four liraglutide-treated (2.9%) patients reported hypoglycaemia, with no event being severe.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the efficacy and safety of once-weekly dulaglutide 0.75 mg monotherapy compared with once-daily liraglutide 0.9 mg in Japanese patients with type 2 diabetes (T2D) for 52 weeks.
Summary · context
The present paper reports results for patients treated with dulaglutide and patients treated with liraglutide for 52 weeks.
Report a problemFND-2666151415

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.

Summary

Results from this study11

Version history

Subjects

Publication types

MeSH terms

Keywords